Laia Hernandez-Oller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laia Hernandez-Oller has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Alba Ricarte
Cardiovascular Surgery, Hospital Clínic, University of Barcelona, Spain
1 shared publication- Alessandro Affronti
Cardiovascular Surgery, Hospital Clínic, University of Barcelona, Spain
1 shared publication Belén Cevallos
Cardiovascular Surgery, Hospital Clínic, University of Barcelona, Spain
1 shared publicationBlanca Domenech-Ximenos
Radiology Department, Hospital Clínic, University of Barcelona, Spain
1 shared publicationBrayan Rubio
Cardiovascular Surgery, Hospital Clínic, University of Barcelona, Spain
1 shared publication- Diana Rafael
Drug Delivery & Targeting, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain
1 shared publication
Latest Publications
- 15 May 2024
- Published by SAGE Publications in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
- Vol. 19 (3) , 318-320
Novel Carbon-Fiber Rigid Fixation for Sternal Closure
- 15 May 2024
- Published by SAGE Publications in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
- Vol. 19 (3) , 318-320
Novel Carbon-Fiber Rigid Fixation for Sternal Closure
- Open Access
- 26 November 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (12) , 1146
Extracellular Vesicles as Drug Delivery Systems in Cancer
Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.
- 26 November 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (12) , 1146
Open AccessExtracellular Vesicles as Drug Delivery Systems in Cancer
Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.